Direct and indirect regulation of β-glucocerebrosidase by the transcription factors USF2 and ONECUT2.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
received:
31
05
2024
accepted:
16
10
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
22
10
2024
Statut:
epublish
Résumé
Mutations in GBA1 encoding the lysosomal enzyme β-glucocerebrosidase (GCase) are among the most prevalent genetic susceptibility factors for Parkinson's disease (PD), with 10-30% of carriers developing the disease. To identify genetic modifiers contributing to the incomplete penetrance, we examined the effect of 1634 human transcription factors (TFs) on GCase activity in lysates of an engineered human glioblastoma line homozygous for the pathogenic GBA1 L444P variant. Using an arrayed CRISPR activation library, we uncovered 11 TFs as regulators of GCase activity. Among these, activation of MITF and TFEC increased lysosomal GCase activity in live cells, while activation of ONECUT2 and USF2 decreased it. While MITF, TFEC, and USF2 affected GBA1 transcription, ONECUT2 might control GCase trafficking. The effects of MITF, TFEC, and USF2 on lysosomal GCase activity were reproducible in iPSC-derived neurons from PD patients. Our study provides a systematic approach to identifying modulators of GCase activity and deepens our understanding of the mechanisms regulating GCase.
Identifiants
pubmed: 39438499
doi: 10.1038/s41531-024-00819-7
pii: 10.1038/s41531-024-00819-7
doi:
Types de publication
Journal Article
Langues
eng
Pagination
192Informations de copyright
© 2024. The Author(s).
Références
Vazquez-Velez, G. E. & Zoghbi, H. Y. Parkinson’s disease genetics and pathophysiology. Annu. Rev. Neurosci. 44, 87–108 (2021).
pubmed: 34236893
doi: 10.1146/annurev-neuro-100720-034518
Morris, H. R., Spillantini, M. G., Sue, C. M. & Williams-Gray, C. H. The pathogenesis of Parkinson’s disease. Lancet 403, 293–304 (2024).
pubmed: 38245249
doi: 10.1016/S0140-6736(23)01478-2
Hannun, Y. A. & Obeid, L. M. Author correction: sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 19, 673 (2018).
pubmed: 30111875
doi: 10.1038/s41580-018-0046-6
Sidransky, E. & Lopez, G. The link between the GBA gene and parkinsonism. Lancet Neurol. 11, 986–998 (2012).
pubmed: 23079555
pmcid: 4141416
doi: 10.1016/S1474-4422(12)70190-4
Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N. Engl. J. Med. 361, 1651–1661 (2009).
pubmed: 19846850
pmcid: 2856322
doi: 10.1056/NEJMoa0901281
Sidransky, E., Samaddar, T. & Tayebi, N. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 73, 1424–1425 (2009).
pubmed: 19858467
doi: 10.1212/WNL.0b013e3181b28601
Billingsley, K. J., Bandres-Ciga, S., Saez-Atienzar, S. & Singleton, A. B. Genetic risk factors in Parkinson’s disease. Cell Tissue Res. 373, 9–20 (2018).
pubmed: 29536161
pmcid: 6201690
doi: 10.1007/s00441-018-2817-y
Blauwendraat, C. et al. Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia. Brain 143, 234–248 (2020).
pubmed: 31755958
doi: 10.1093/brain/awz350
Do, J., McKinney, C., Sharma, P. & Sidransky, E. Glucocerebrosidase and its relevance to Parkinson disease. Mol. Neurodegener. 14, 36 (2019).
pubmed: 31464647
pmcid: 6716912
doi: 10.1186/s13024-019-0336-2
Gan-Or, Z. et al. The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease. J. Neurol. 262, 2443–2447 (2015).
pubmed: 26233692
doi: 10.1007/s00415-015-7868-3
Jinn, S. et al. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases alpha-synuclein aggregation. Proc. Natl Acad. Sci. USA 114, 2389–2394 (2017).
pubmed: 28193887
pmcid: 5338534
doi: 10.1073/pnas.1616332114
Krohn, L. et al. Genetic, structural, and functional evidence link TMEM175 to synucleinopathies. Ann. Neurol. 87, 139–153 (2020).
pubmed: 31658403
doi: 10.1002/ana.25629
Manolio, T. A. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363, 166–176 (2010).
pubmed: 20647212
doi: 10.1056/NEJMra0905980
Lambert, S. A. et al. The human transcription factors. Cell 175, 598–599 (2018).
pubmed: 30290144
doi: 10.1016/j.cell.2018.09.045
Settembre, C. & Perera, R. M. Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology. Nat. Rev. Mol. Cell Biol. https://doi.org/10.1038/s41580-023-00676-x (2023).
Sardiello, M. et al. A gene network regulating lysosomal biogenesis and function. Science 325, 473–477 (2009).
pubmed: 19556463
doi: 10.1126/science.1174447
Blech-Hermoni, Y. N. et al. In silico and functional studies of the regulation of the glucocerebrosidase gene. Mol. Genet Metab. 99, 275–282 (2010).
pubmed: 20004604
doi: 10.1016/j.ymgme.2009.10.189
Kampmann, M. A CRISPR approach to neurodegenerative diseases. Trends Mol. Med. 23, 483–485 (2017).
pubmed: 28478951
pmcid: 5604856
doi: 10.1016/j.molmed.2017.04.003
Kampmann, M. CRISPR-based functional genomics for neurological disease. Nat. Rev. Neurol. 16, 465–480 (2020).
pubmed: 32641861
pmcid: 7484261
doi: 10.1038/s41582-020-0373-z
Tian, R. et al. CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. Neuron 104, 239–255.e212 (2019).
pubmed: 31422865
pmcid: 6813890
doi: 10.1016/j.neuron.2019.07.014
Yin, J.-A. et al. Robust and versatile arrayed libraries for human genome-wide CRISPR activation, deletion and silencing. bioRxiv, 2022.2005.2025.493370. https://doi.org/10.1101/2022.05.25.493370 (2023).
Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016).
pubmed: 27397505
pmcid: 4967469
doi: 10.1016/j.cell.2016.06.017
Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883–891 (2020).
pubmed: 32433547
pmcid: 7357821
doi: 10.1038/s41587-020-0453-z
Bendikov-Bar, I., Ron, I., Filocamo, M. & Horowitz, M. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol. Dis. 46, 4–10 (2011).
pubmed: 21106416
doi: 10.1016/j.bcmd.2010.10.012
Bendikov-Bar, I. & Horowitz, M. Gaucher disease paradigm: from ERAD to comorbidity. Hum. Mutat. 33, 1398–1407 (2012).
pubmed: 22623374
doi: 10.1002/humu.22124
Lu, J. et al. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc. Natl Acad. Sci. USA 108, 21200–21205 (2011).
pubmed: 22160715
pmcid: 3248545
doi: 10.1073/pnas.1119181109
Goker-Alpan, O. et al. Divergent phenotypes in Gaucher disease implicate the role of modifiers. J. Med. Genet 42, e37 (2005).
pubmed: 15937077
pmcid: 1736082
doi: 10.1136/jmg.2004.028019
Straniero, L. et al. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Sci. Rep. 7, 12702 (2017).
pubmed: 28983119
pmcid: 5629250
doi: 10.1038/s41598-017-12973-5
Davidson, B. A., Hassan, S., Garcia, E. J., Tayebi, N. & Sidransky, E. Exploring genetic modifiers of Gaucher disease: the next horizon. Hum. Mutat. 39, 1739–1751 (2018).
pubmed: 30098107
pmcid: 6240360
doi: 10.1002/humu.23611
Ysselstein, D. et al. Evaluation of strategies for measuring lysosomal glucocerebrosidase activity. Mov. Disord. 36, 2719–2730 (2021).
pubmed: 34613624
pmcid: 8853444
doi: 10.1002/mds.28815
Deen, M. C. et al. Selective fluorogenic beta-glucocerebrosidase substrates for convenient analysis of enzyme activity in cell and tissue homogenates. ACS Chem. Biol. 15, 824–829 (2020).
pubmed: 32109051
doi: 10.1021/acschembio.9b01044
Deen, M. C. et al. A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells. Proc. Natl Acad. Sci. USA 119, e2200553119 (2022).
pubmed: 35858317
pmcid: 9304032
doi: 10.1073/pnas.2200553119
Breiden, B. & Sandhoff, K. Lysosomal glycosphingolipid storage diseases. Annu Rev. Biochem. 88, 461–485 (2019).
pubmed: 31220974
doi: 10.1146/annurev-biochem-013118-111518
Kuo, C. L. et al. In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling. FEBS J. 286, 584–600 (2019).
pubmed: 30600575
pmcid: 6850446
doi: 10.1111/febs.14744
Sultana, S. et al. Characterization of the zebrafish homolog of beta-glucosidase 2: a target of the drug miglustat. Zebrafish 13, 177–187 (2016).
pubmed: 26909767
doi: 10.1089/zeb.2015.1152
Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4, 67–73 (1999).
pubmed: 10838414
doi: 10.1177/108705719900400206
Ron, I. & Horowitz, M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14, 2387–2398 (2005).
pubmed: 16000318
doi: 10.1093/hmg/ddi240
Pastore, N. et al. TFE3 regulates whole-body energy metabolism in cooperation with TFEB. EMBO Mol. Med. 9, 605–621 (2017).
pubmed: 28283651
pmcid: 5412821
doi: 10.15252/emmm.201607204
Raben, N. & Puertollano, R. TFEB and TFE3: linking lysosomes to cellular adaptation to stress. Annu Rev. Cell Dev. Biol. 32, 255–278 (2016).
pubmed: 27298091
pmcid: 6490169
doi: 10.1146/annurev-cellbio-111315-125407
Cecioni, S. et al. Quantifying lysosomal glycosidase activity within cells using bis-acetal substrates. Nat. Chem. Biol. 18, 332–341 (2022).
pubmed: 35210619
doi: 10.1038/s41589-021-00960-x
Yamanaka, T. et al. Genome-wide analyses in neuronal cells reveal that upstream transcription factors regulate lysosomal gene expression. FEBS J. 283, 1077–1087 (2016).
pubmed: 26756308
doi: 10.1111/febs.13650
Vu, H. N., Dilshat, R., Fock, V. & Steingrimsson, E. User guide to MiT-TFE isoforms and post-translational modifications. Pigment Cell Melanoma Res. 34, 13–27 (2021).
pubmed: 32846025
doi: 10.1111/pcmr.12922
Gupta, M. et al. Plekhg4 is a novel Dbl family guanine nucleotide exchange factor protein for rho family GTPases. J. Biol. Chem. 288, 14522–14530 (2013).
pubmed: 23572525
pmcid: 3656306
doi: 10.1074/jbc.M112.430371
Yuan, Q. et al. Pleckstrin homology and RhoGEF domain containing G4 (PLEKHG4) leads to the activation of RhoGTPases promoting the malignant phenotypes of thyroid cancer. Apoptosis 28, 1315–1331 (2023).
pubmed: 37336836
doi: 10.1007/s10495-023-01861-1
Fornes, O. et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 48, D87–D92 (2020).
pubmed: 31701148
Corre, S. & Galibert, M. D. USF as a key regulatory element of gene expression. Med. Sci. 22, 62–67 (2006).
Annunziata, I. et al. MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat. Nat. Commun. 10, 3623 (2019).
pubmed: 31399583
pmcid: 6689058
doi: 10.1038/s41467-019-11568-0
Braunstein, H. et al. UPR activation and CHOP mediated induction of GBA1 transcription in Gaucher disease. Blood Cells Mol. Dis. 68, 21–29 (2018).
pubmed: 27856178
doi: 10.1016/j.bcmd.2016.10.025
Sapkota, D. et al. Onecut1 and Onecut2 redundantly regulate early retinal cell fates during development. Proc. Natl Acad. Sci. USA 111, E4086–E4095 (2014).
pubmed: 25228773
pmcid: 4191802
doi: 10.1073/pnas.1405354111
Vanhorenbeeck, V. et al. Role of the Onecut transcription factors in pancreas morphogenesis and in pancreatic and enteric endocrine differentiation. Dev. Biol. 305, 685–694 (2007).
pubmed: 17400205
doi: 10.1016/j.ydbio.2007.02.027
Jacquemin, P. et al. The transcription factor onecut-2 controls the microphthalmia-associated transcription factor gene. Biochem. Biophys. Res. Commun. 285, 1200–1205 (2001).
pubmed: 11478782
doi: 10.1006/bbrc.2001.5294
Boddupalli, C. S. et al. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. Elife 11, e79830 (2022).
Brunialti, E. et al. Inhibition of microglial beta-glucocerebrosidase hampers the microglia-mediated antioxidant and protective response in neurons. J. Neuroinflamm. 18, 220 (2021).
doi: 10.1186/s12974-021-02272-2
Williams, D. et al. Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson’s disease. bioRxiv, 2024.2003.2022.586364. https://doi.org/10.1101/2024.03.22.586364 (2024).
Tamargo, R. J., Velayati, A., Goldin, E. & Sidransky, E. The role of saposin C in Gaucher disease. Mol. Genet. Metab. 106, 257–263 (2012).
pubmed: 22652185
pmcid: 3534739
doi: 10.1016/j.ymgme.2012.04.024
Mecca, C., Giambanco, I., Donato, R. & Arcuri, C. Targeting mTOR in glioblastoma: rationale and preclinical/clinical evidence. Dis. Markers 2018, 9230479 (2018).
pubmed: 30662577
pmcid: 6312595
doi: 10.1155/2018/9230479
Goding, C. R. & Arnheiter, H. MITF-the first 25 years. Genes Dev. 33, 983–1007 (2019).
pubmed: 31123060
pmcid: 6672050
doi: 10.1101/gad.324657.119
Henley, M. J. & Koehler, A. N. Advances in targeting ‘undruggable’ transcription factors with small molecules. Nat. Rev. Drug Discov. 20, 669–688 (2021).
pubmed: 34006959
doi: 10.1038/s41573-021-00199-0
Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224–226 (2019).
pubmed: 30809026
pmcid: 6533916
doi: 10.1038/s41587-019-0032-3
Goddard-Borger, E. D. et al. Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease. J. Med. Chem. 55, 2737–2745 (2012).
pubmed: 22360565
pmcid: 3380069
doi: 10.1021/jm201633y
Lambert, S. A. et al. The human transcription factors. Cell 172, 650–665 (2018).
pubmed: 29425488
doi: 10.1016/j.cell.2018.01.029
Hatakeyama, M. et al. SUSHI: an exquisite recipe for fully documented, reproducible and reusable NGS data analysis. BMC Bioinforma. 17, 228 (2016).
doi: 10.1186/s12859-016-1104-8
Hildebrandt, M. R. et al. Precision health resource of control iPSC lines for versatile multilineage differentiation. Stem Cell Rep. 13, 1126–1141 (2019).
doi: 10.1016/j.stemcr.2019.11.003
Zhang, X. D. Illustration of SSMD, z score, SSMD*, z* score, and t statistic for hit selection in RNAi high-throughput screens. J. Biomol. Screen 16, 775–785 (2011).
pubmed: 21515799
doi: 10.1177/1087057111405851